Photo by atikahakhtar from unsplash
Adalimumab (Humira®, AbbVie Inc., North Chicago, IL, U.S.A.) is a fully human monoclonal antibody specific for tumour necrosis factor‐α that is approved to treat adults with moderate‐to‐severe chronic plaque psoriasis. Click to show full abstract
Adalimumab (Humira®, AbbVie Inc., North Chicago, IL, U.S.A.) is a fully human monoclonal antibody specific for tumour necrosis factor‐α that is approved to treat adults with moderate‐to‐severe chronic plaque psoriasis.
Keywords:
long term;
comprehensive long;
plaque psoriasis;
moderate severe
Journal Title: British Journal of Dermatology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Dermatology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!